# Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC

> **NCT05901584** · PHASE2 · UNKNOWN · sponsor: **Second Affiliated Hospital of Zunyi Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Immunotherapy
- Second-line Treatment

## Interventions

- **DRUG:** Cadonilimab

## Key facts

- **NCT ID:** NCT05901584
- **Lead sponsor:** Second Affiliated Hospital of Zunyi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-01
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-06-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05901584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05901584, "Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05901584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*